DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2+mBC

被引：0

作者：

Andre, Fabrice

Hamilton, Erika P.

Loi, Sherene

Anders, Carey K.

Schmid, Peter

Stroyakovskiy, Daniil

Villanueva, Rafael

Pedrini, Jose Luiz

Doval, Dinesh Chandra

Zurawski, Bogdan

Chen, Shin-Cheh

Boston, Sarice Renee

Konpa, Adam

Pierotti, Barbara

Fabbri, Giulia

Jhaveri, Komal L.

机构：

[1] Univ Paris Saclay, Gustave Roussy, Villejuif, France

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Peter MacCallum Canc Ctr, Melbourne, Australia

[4] Duke Canc Inst, Durham, NC USA

[5] Queen Mary Univ London, Barts Canc Inst, London, England

[6] Moscow City Oncol Hosp 62, Moscow, Russia

[7] ICO Hosp, Barcelona, Spain

[8] Nossa Senhora Conceicao Hosp, Porto Alegre, Brazil

[9] Rajiv Gandhi Canc Inst & Res Ctr, New Delhi, India

[10] F Lukaszczyk Oncol Ctr, Bydogoszcz, Poland

[11] Linkou Chang Gung Mem Hosp, Dept Gen Surg & Breast Surg, Taoyuan, Taiwan

[12] AstraZeneca, Gaithersburg, MD USA

[13] AstraZeneca, Warsaw, Mazowieckie, Poland

[14] AstraZeneca, Boston, MA USA

[15] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1009

引用

页数：1

共 50 条

[21] A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03 [J].

Hurvitz, S. A. ;

Modi, S. ;

Li, W. ;

Park, Y. H. ;

Chung, W. ;

Kim, S-B. ;

Cortes, J. ;

Yamashita, T. ;

Pedrini, J. ;

Im, S-A. ;

Tseng, L-M. ;

Harbeck, N. ;

Krop, I. ;

Curigliano, G. ;

Mathias, E. ;

Cathcart, J. ;

Cagnazzo, A. ;

Ashfaque, S. ;

Egorov, A. ;

Andre, F. .

ANNALS OF ONCOLOGY, 2023, 34 :S335-S336

[22] Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07) [J].

Hamilton, Erika ;

Jhaveri, Komal ;

Loi, Sherene ;

Anders, Carey ;

Schmid, Peter ;

Penkov, Konstantin ;

Artamonova, Elena ;

Zhukova, Lyudmila ;

Stroyakovsky, Daniil L. ;

Doval, Dinesh Chandra ;

Villanueva, Rafael ;

Michelini, Flavia ;

Chandarlapaty, Sarat ;

Wilson, Matt ;

Boston, Sarice R. ;

Konpa, Adam ;

Mondal, Shoubhik ;

Andre, Fabrice .

CANCER RESEARCH, 2023, 83 (05)

[23] A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC) [J].

Kumar, Prashanth Ashok ;

Sandhu, Michael ;

Sravanthi, Metlapalli Venkata ;

Kumar, Vishnu Charan Suresh ;

Benjamin, Sam .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[24] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study [J].

Cortes, J. ;

Kim, S-B. ;

Chung, W-P. ;

Im, S-A. ;

Park, Y. H. ;

Hegg, R. ;

Kim, M. H. ;

Tseng, L-M. ;

Petry, V. ;

Chung, C-F. ;

Iwata, H. ;

Hamilton, E. ;

Curigliano, G. ;

Xu, B. ;

Lee, C. ;

Liu, Y. ;

Cathcart, J. ;

Bako, E. ;

Verma, S. ;

Hurvitz, S. A. .

ANNALS OF ONCOLOGY, 2021, 32 :S1287-S1288

[25] Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd) [J].

Powell, C. A. ;

Modi, S. ;

Iwata, H. ;

Takahashi, S. ;

Nie, K. ;

Qin, A. ;

Singh, J. ;

Taitt, C. ;

Verma, S. ;

Camidge, D. R. .

ANNALS OF ONCOLOGY, 2021, 32 :S61-S62

[26] A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03). [J].

Janjigian, Yelena Y. ;

Viglianti, Natasha ;

Liu, Feng ;

Mendoza-Naranjo, Ariadna ;

Croydon, Liz .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

[27] A phase Ib/II, multicenter, open-label, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd; DS8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03) [J].

Janjigian, Y. Y. ;

Viglianti, N. ;

Liu, F. ;

Mendoza-Naranjo, A. ;

Puvvada, S. .

ANNALS OF ONCOLOGY, 2020, 31 :S930-S931

[28] Rescue Therapy with Trastuzumab Deruxtecan (T-Dxd) in Patients with primary hepatic metastatic Her2 low Breast Cancer with marked Hyperbilirubinemia [J].

Wolf, M. ;

Sili, F. ;

Sulejmani, V. ;

Schuepferling, A. ;

Bomhard, J. ;

Huber, M. ;

Sigl, S. ;

Schnelzer, A. .

GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) :E44-E44

[29] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. [J].

Meric-Bernstam, Funda ;

Makker, Vicky ;

Oaknin, Ana ;

Oh, Do-Youn ;

Banerjee, Susana N. ;

Martin, Antonio Gonzalez ;

Jung, Kyung Hae ;

Lugowska, Iwona A. ;

Manso, Luis ;

Manzano, Aranzazu ;

Melichar, Bohuslav ;

Siena, Salvatore ;

Stroyakovskiy, Daniil ;

Anoka, Chiedozie ;

Ma, Yan ;

Puvvada, Soham D. ;

Lee, Jung-Yun .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) :LBA3000-LBA3000

[30] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results [J].

Lin, N. ;

Ciruelos, E. M. ;

Jerusalem, G. ;

Mueller, V. ;

Niikura, N. ;

Viale, G. ;

Bartsch, R. ;

Kurzeder, C. ;

Connolly, R. ;

Baron-Hay, S. E. ;

Cortes, M. Gion ;

Guarneri, V. ;

Bianchini, G. ;

Wildiers, H. ;

Escriva-de-Romani, S. ;

Prahladan, M. ;

Bridge, H. ;

Verma, S. ;

Harbeck, N. .

ANNALS OF ONCOLOGY, 2024, 35 :1211-1212

← 1 2 3 4 5 →